429 related articles for article (PubMed ID: 9669503)
21. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
22. Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors.
Tang KM; Jang EK; Haslam RJ
Eur J Pharmacol; 1994 Jun; 268(1):105-14. PubMed ID: 7925608
[TBL] [Abstract][Full Text] [Related]
23. Properties of adenylate cyclase and cyclic nucleotide phosphodiesterase in hamster isolated capillary preparations.
Nemecek GM
Biochim Biophys Acta; 1980 Mar; 628(2):125-35. PubMed ID: 6244001
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
[TBL] [Abstract][Full Text] [Related]
25. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
Sudo T; Tachibana K; Toga K; Tochizawa S; Inoue Y; Kimura Y; Hidaka H
Biochem Pharmacol; 2000 Feb; 59(4):347-56. PubMed ID: 10644042
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms involved in the antiplatelet activity of 8-methyl-4-(1-piperazinyl)-7-(3-pyridinylmethoxy)-2H-1-benzopyran-2-one (RC414).
Leoncini G; Signorello MG; Bruzzese D; Di Braccio M; Grossi GC; Roma G
Biochem Pharmacol; 2004 Mar; 67(5):911-8. PubMed ID: 15104244
[TBL] [Abstract][Full Text] [Related]
27. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
Souness JE; Diocee BK; Martin W; Moodie SA
Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
[TBL] [Abstract][Full Text] [Related]
28. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
Mikashima H; Nakao T; Goto K; Ochi H; Yasuda H; Tsumagari T
Thromb Res; 1984 Sep; 35(5):589-94. PubMed ID: 6091293
[TBL] [Abstract][Full Text] [Related]
29. Mepacrine-induced inhibition of human platelet cyclic-GMP phosphodiesterase.
Yamakado T; Tanaka F; Hidaka H
Biochim Biophys Acta; 1984 Sep; 801(1):111-6. PubMed ID: 6147162
[TBL] [Abstract][Full Text] [Related]
30. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
31. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Ahn HS; Eardley D; Watkins R; Prioli N
Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
[TBL] [Abstract][Full Text] [Related]
32. Antiplatelet Activity of a Newly Synthesized Novel Ruthenium (II): A Potential Role for Akt/JNK Signaling.
Khamrang T; Hung KC; Hsia CH; Hsieh CY; Velusamy M; Jayakumar T; Sheu JR
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28448438
[TBL] [Abstract][Full Text] [Related]
33. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.
Torphy TJ; Zhou HL; Burman M; Huang LB
Mol Pharmacol; 1991 Mar; 39(3):376-84. PubMed ID: 1848659
[TBL] [Abstract][Full Text] [Related]
34. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
35. Effects of Ca2+ and calmodulin on cyclic nucleotide metabolism in neurosecretosomes isolated from ox neurohypophyses.
Dartt DA; Torp-Pedersen C; Thorn NA
Brain Res; 1981 Jan; 204(1):121-8. PubMed ID: 6113872
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of cyclooxygenase activity and increase in platelet cyclic AMP by girinimbine, isolated from Murraya euchrestifolia.
Ko FN; Lee YS; Wu TS; Teng CM
Biochem Pharmacol; 1994 Jul; 48(2):353-60. PubMed ID: 8053931
[TBL] [Abstract][Full Text] [Related]
37. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
Lavan BE; Lakey T; Houslay MD
Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
[TBL] [Abstract][Full Text] [Related]
38. Antiplatelet effect of amlodipine: a possible mechanism through a nitric oxide-mediated process.
Chou TC; Li CY; Yen MH; Ding YA
Biochem Pharmacol; 1999 Nov; 58(10):1657-63. PubMed ID: 10535758
[TBL] [Abstract][Full Text] [Related]
39. Age-induced differentiation of morphine's effect on cyclic nucleotide metabolism.
Hoskins B; Ho IK
Neurobiol Aging; 1987; 8(5):473-6. PubMed ID: 2891056
[TBL] [Abstract][Full Text] [Related]
40. Studies on antiplatelet effects of OP-41483, a prostaglandin I2 analog, in experimental animals. II. Mechanism of its antiplatelet effect.
Fujitani B; Wakitani K
Jpn J Pharmacol; 1990 May; 53(1):25-33. PubMed ID: 2161965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
